Answers are grounded in this paper and cite their sources.
Target trial emulation shows longer SGLT2i treatment reduces cardiovascular events in type 2 diabetes patients, suggesting sustained use is beneficial.
Introduction and Objective: Despite cardiovascular benefits of sodium-glucose cotransporter 2 inhibitors (SGLT2i), treatment persistence is suboptimal in routine clinical practice. We investigated whether longer treatment durations offer greater cardiovascular benefits. Methods: We used nationwide healthcare data of South Korea (2012-2023) to emulate a target trial comparing following treatment strategies: treated with SGLT2i for <1 year, 1-2 years, 2-3 years, and ≥3 years among patients with type 2 diabetes. Primary outcomes were major adverse cardiovascular events (MACE) and hospitalization for heart failure (HHF). Cloning, censoring, and weighting methods were applied, and 5-year absolute risks, risk differences, and risk ratios were estimated using weighted Kaplan-Meier methods. Results: 1,174,088 eligible patients initiating SGLT2i were identified (mean age 57.3 years; 40.5% female). Compared to patients treated with SGLT2i for <1 year, those treated for 1-2 years, 2-3 years, and ≥3 years had progressively lower risks of MACE (RRs: 0.93 [95% CI, 0.90-0.96], 0.82 [0.78-0.85], and 0.69 [0.67-0.72], respectively) and HHF (RRs: 0.93 [0.90-0.97], 0.91 [0.80-0.99], and 0.74 [0.67-0.79], respectively) over a 5-year follow-up. Conclusion: Longer SGLT2i use was associated with progressively lower cardiovascular risk, highlighting cardioprotective benefits of sustained treatment. Disclosure B. Hong: None. K. Jung: None. H. Lee: None. J. Bae: None. Y. Cho: Other - Outside director; Current; Daewoong Pharmaceuticals, Korea. Advisory Panel; Ended; Hanmi Pharm. Co., Ltd.
No takes yet. Share an insight, caveat, or question.
Hong et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: